- Conditions
- Glabellar Frown Lines
- Interventions
- AbobotulinumtoxinA dose level 1 or 2, placebo, AbobotulinumtoxinA dose 3, AbobotulinumtoxinA dose 4
- Biological · Other
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 401 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 10
- States / cities
- Encino, California • Manhattan Beach, California • Vista, California + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2809–2832
of 17,854
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Multiple Myeloma
- Interventions
- Ixazomib, Lenalidomide, Dexamethasone
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 20
- States / cities
- Berkeley, California • Duarte, California • Stanford, California + 15 more
- Conditions
- Trauma, Psychological, Trauma and Stressor Related Disorders
- Interventions
- Trauma-Focused Cognitive Behavioral Therapy (TF-CBT), School-Adapted TF-CBT (S-TF)
- Behavioral
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 7 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Deucravacitinib, Placebo
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 513 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 39
- States / cities
- La Jolla, California • La Mesa, California • San Diego, California + 34 more
- Conditions
- Metastatic Colorectal Carcinoma (mCRC), Colorectal Cancer (CRC), Adenomatous Polyposis Coli (APC) Gene Mutation, Catenin Beta-1 (CTNNB1) Gene Mutation
- Interventions
- Tegavivint
- Drug
- Lead sponsor
- HonorHealth Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Spontaneous Bacterial Peritonitis, Cirrhosis
- Interventions
- Standard Care, Experimental
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
- Interventions
- 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, cisplatin, etoposide
- Radiation · Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- Not listed
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Influenza
- Interventions
- Seasonal Influenza DNA vaccine, TIV
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • St Louis, Missouri • Lebanon, New Hampshire + 2 more
- Conditions
- Lymphoma
- Interventions
- rituximab, vinorelbine ditartrate
- Biological · Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2005
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Glabellar Lines
- Interventions
- AGN-151586
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 992 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Los Angeles, California + 36 more
- Conditions
- Castration-resistant Prostate Cancer, CRPC
- Interventions
- VT-464: given orally once daily in 28 day cycles
- Drug
- Lead sponsor
- Innocrin Pharmaceutical
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 5
- States / cities
- Tampa, Florida • Omaha, Nebraska • Durham, North Carolina + 2 more
- Conditions
- Chronic Myeloid Leukemia
- Interventions
- nilotinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2025
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Beech Grove, Indiana • Baltimore, Maryland + 2 more
- Conditions
- Healthy Participants
- Interventions
- E2730, Placebo
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Chronic Hepatitis C
- Interventions
- BMS-790052, BMS-650032, Pegylated-interferon alfa-2a, Ribavirin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 215 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 10
- States / cities
- Anaheim, California • Coronado, California • San Jose, California + 7 more
- Conditions
- Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration, Low Grade Glioma of Brain With Neurofibromatosis Type 1
- Interventions
- Dabrafenib, Trametinib, Hydroxychloroquine
- Drug
- Lead sponsor
- Pediatric Brain Tumor Consortium
- Network
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 12 more
- Conditions
- Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
- Interventions
- Inhaled NO delivered via INOpulse DS-C Device, Placebo delivered via INOpulse DS-C Device
- Combination Product
- Lead sponsor
- Bellerophon Pulse Technologies
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 43
- States / cities
- Jasper, Alabama • Flagstaff, Arizona • Phoenix, Arizona + 35 more
- Conditions
- Late Life Depression, Cognitive Decline, Depressive Disorder, Treatment-Resistant, Levodopa, Gait Impairment
- Interventions
- L-Dopa, Placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania • Nashville, Tennessee
- Conditions
- Cystic Fibrosis
- Interventions
- VX-659/TEZ/IVA, IVA
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 484 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 44 more
- Conditions
- Advanced Solid Tumors, Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Gastroesophageal Junction Cancer
- Interventions
- MRG002
- Drug
- Lead sponsor
- Shanghai Miracogen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 2
- States / cities
- Orange, California • Houston, Texas
- Conditions
- Melanoma (Skin)
- Interventions
- MART-1, NY-ESO-1, gp100:209-217(210M), gp100:280-288(288V), Montanide ISA 51 VG, BMS-936558
- Biological · Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Bronchiolitis Obliterans, Graft Vs Host Disease
- Interventions
- Pirfenidone 267 MG [Esbriet]
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Nausea, Vomiting
- Interventions
- aprepitant, Ondansetron
- Drug
- Lead sponsor
- University of Vermont
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Winston-Salem, North Carolina • Burlington, Vermont
- Conditions
- Undefined
- Interventions
- MyMD1, Placebo
- Drug
- Lead sponsor
- TNF Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- West Palm Beach, Florida
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- PET/MRI, Percutaneous ablation, Stereotactic body radiotherapy
- Device · Radiation
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- St Louis, Missouri